Advanced or Metastatic Non-small Cell Lung Cancer Clinical Trials

5 recruiting

Advanced or Metastatic Non-small Cell Lung Cancer Trials at a Glance

10 actively recruiting trials for advanced or metastatic non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Beijing, San Antonio, and Adelaide. Lead sponsors running advanced or metastatic non-small cell lung cancer studies include AstraZeneca, Jiangsu HengRui Medicine Co., Ltd., and Allist Pharmaceuticals, Inc..

Browse advanced or metastatic non-small cell lung cancer trials by phase

Treatments under study

About Advanced or Metastatic Non-small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Advanced or Metastatic Non-small Cell Lung Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced or Metastatic Non-small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced or Metastatic Non-small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled104 locationsNCT06996782
Recruiting
Phase 2

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.120 enrolled1 locationNCT06955988
Recruiting
Phase 1Phase 2

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Advanced or Metastatic Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.248 enrolled1 locationNCT06512051
Recruiting
Phase 2

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Locally Advanced or Metastatic Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.200 enrolled1 locationNCT07175220
Recruiting
Phase 3

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.460 enrolled1 locationNCT07170995
Recruiting
Phase 1

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Metastatic Breast CancerAdvanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)+3 more
Olema Pharmaceuticals, Inc.180 enrolled8 locationsNCT06784193
Recruiting
Phase 1Phase 2

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Advanced Malignant NeoplasmAdvanced or Metastatic Non-small Cell Lung Cancer
SUNHO(China)BioPharmaceutical CO., Ltd.78 enrolled1 locationNCT06581419
Recruiting
Phase 3

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Advanced or Metastatic Non-small Cell Lung Cancer
Peking Union Medical College Hospital144 enrolled1 locationNCT06674343
Recruiting
Phase 1Phase 2

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Non-small Cell Lung CancerLocally Advanced or Metastatic Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.360 enrolled1 locationNCT04996121